OncBioMune Pharmaceuticals

OncBioMune specializes in innovative cancer research. The Company owns the proprietary rights to a therapeutic cancer vaccine and patent-pending targeted therapies. The Company’s vaccines have been proven to be effective in cancer patients with virtually no toxicity, clearing a major hurdle in immunotherapy and oncology and positioning OncBioMune to deliver a new standard of cancer care. Using tumor antigens to immunize patients, OncBioMune’s vaccines can be used as a stand-alone therapeutic or as an adjunct to today’s or future cancer treatments to boost the immune system to attack cancer cells in relapsed, refractory or simply at-risk patients. The Company's approaches slow tumor cell proliferation, help avoid relapse, overcomes drug resistance and extends progression-free and overall survival.